Is there room for non-dopaminergic treatment in Parkinson disease?

Abraham Lieberman, Narayanan Krishnamurthi

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Although levodopa and dopaminergic drugs remain the mainstay of therapy for the motor symptoms of Parkinson disease (PD), they fail to address many of the non-motor symptoms of PD including orthostatic hypotension, freezing of gait (FOG) and difficulty with balance, drug-induced paranoia and hallucinations, and drug-induced dyskinesias. Droxidopa, a drug that increases norepinephrine, treats orthostatic hypotension, cholinomimetic drugs sometimes help with FOG and difficulty with balance, pimavanserin, a drug that blocks serotonin receptors, treats paranoia and hallucinations, and anti-glutaminergic drugs treat dyskinesias. Thus, there are ample opportunities for non-dopaminergic drugs in PD.

Original languageEnglish (US)
Pages (from-to)347-348
Number of pages2
JournalJournal of Neural Transmission
Issue number2
StatePublished - Feb 1 2013
Externally publishedYes


  • Levodopa
  • Non-dopaminergic drugs
  • Non-motor symptoms
  • Parkinson disease

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'Is there room for non-dopaminergic treatment in Parkinson disease?'. Together they form a unique fingerprint.

Cite this